Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

26.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

741
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026
Same author

Emerging Treatments and Novel Modalities in Head and Neck Cancers.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

HSR26-209: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Qualitative Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

BIO26-042: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Pilot Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.

BMJ oncology·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Oct 17, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

543

TCR gene-engineered cell therapy for solid tumors.

Elaine Tan1, Neel Gakhar2, Kedar Kirtane1

  • 1Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA.

Best Practice & Research. Clinical Haematology
|October 9, 2021
PubMed
Summary
This summary is machine-generated.

T cell receptor (TCR) gene engineered therapy shows promise for solid tumors by engineering immune cells to target cancer. Ongoing clinical trials aim to overcome challenges for this cellular immunotherapy approach.

Keywords:
Cellular therapySolid tumorsTCR

More Related Videos

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

884

Related Experiment Videos

Last Updated: Oct 17, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

543
Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

884

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Cellular immunotherapy engineering immune cells to target cancer is advancing.
  • T cell receptor (TCR) gene engineered therapy is a promising cellular therapy for solid tumors.

Purpose of the Study:

  • To review the potential of TCR-based cellular therapies in solid tumors.
  • To discuss the challenges and ongoing clinical trials for TCR T cell therapy.

Main Methods:

  • Review of current literature on TCR gene engineered therapy.
  • Analysis of TCR T cell mechanisms involving heterodimers, intracellular tumor antigens, and MHC presentation.

Main Results:

  • TCR T cells can recognize intracellular tumor antigens via MHC.
  • These engineered cells can elicit cytotoxic and clinical responses against tumors.

Conclusions:

  • TCR-based cellular therapies hold significant potential for treating solid tumors.
  • Despite existing challenges, numerous clinical trials are actively addressing limitations and advancing the field.